A test sheet for occult blood includes a permeable substrate layer, a test layer, and an outer layer. The permeable substrate layer and the test layer are jointed side by side or stacked from top to bottom on the outer layer. The permeable substrate layer is configured to carry biologic sample, and the test layer includes test agent. The outer layer protects the user from the biologic sample. At least one fold line is formed on the front surface of the connection of the permeable substrate layer and the test layer, or alternatively, on the front surface of the permeable substrate layer. When the test sheet is folded along the fold line, the biologic sample permeates the permeable substrate layer and reacts with the test agent. If the reaction causes color change, the biologic sample is determined to contain occult blood.

The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.

The present invention relates to the field of treating iron deficiency with IV iron carbohydrate complexes such ferric carboxymaltose, monitoring or identifying subjects to determine their eligibility for being administered said IV iron carbohydrate complexes, and combining said IV iron carbohydrate complexes with additional drugs in order to mitigate or reduce side effects induced by said IV iron carbohydrate complexes.

A lateral flow immunoassay (LFIA) strip comprises a sample pad (2) for receiving a sample and at least one conjugate pad (3) in operable contact with the sample pad. The at least one conjugate pad is loaded with a first antibody specific against ferritin and tagged with detectable label. A flow-through assay device for detecting ferritin levels in a sample is also provided comprising a sample pad (10) for receiving a sample and at least one conjugate pad (11) in operable contact with the sample pad. The at least one conjugate pad is loaded with a first antibody specific against ferritin and tagged with detectable label. An assay platform (12) is in operable contact with the at least one conjugate pad. The assay platform comprises a substrate having a test region onto which the first test antibody to the ferritin is immobilized. A method for measuring the level of ferritin in a sample is also provided. The sample may be a blood or saliva sample.

A lateral flow immunoassay (LFIA) strip comprises a sample pad (2) for receiving a sample and at least one conjugate pad (3) in operable contact with the sample pad. The at least one conjugate pad is loaded with a first antibody specific against ferritin and tagged with detectable label. A flow-through assay device for detecting ferritin levels in a sample is also provided comprising a sample pad (10) for receiving a sample and at least one conjugate pad (11) in operable contact with the sample pad. The at least one conjugate pad is loaded with a first antibody specific against ferritin and tagged with detectable label. An assay platform (12) is in operable contact with the at least one conjugate pad. The assay platform comprises a substrate having a test region onto which the first test antibody to the ferritin is immobilized. A method for measuring the level of ferritin in a sample is also provided. The sample may be a blood or saliva sample.

The present invention relates to compounds and compositions that can be used in the treatment and diagnosis of anaemias, particularly haemolytic anaemias such as sickle cell anaemia. Methods of selecting such compounds and compositions are also provided.

The present invention relates to compounds and compositions that can be used in the treatment and diagnosis of anaemias, particularly haemolytic anaemias such as sickle cell anaemia. Methods of selecting such compounds and compositions are also provided.

The present invention relates to the field of treating iron deficiency with IV iron carbohydrate complexes such ferric carboxymaltose, monitoring or identifying subjects to determine their eligibility for being administered said IV iron carbohydrate complexes, and combining said IV iron carbohydrate complexes with additional drugs in order to mitigate or reduce side effects induced by said IV iron carbohydrate complexes.

In certain aspects, the present invention provides methods for dosing a patient with an activin-ActRIIa antagonist and methods for managing patients treated with an activin-ActRIIa antagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.

In certain aspects, the present invention provides methods for dosing a patient with an activin-ActRIIa antagonist and methods for managing patients treated with an activin-ActRIIa antagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.